Artículos publicados

Artículos publicados Encontrados 2 registros  La búsqueda tardó 0.00 segundos. 
1.
11 p, 388.8 KB Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab / Arnold, D (Instituto CUF de Oncologia (I.C.O.), Lisboa) ; Fuchs, C S (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona) ; Ohtsu, A (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Zhu, A X (Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA) ; Garon, E B (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ; Mackey, J R (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ; Paz Ares, L (Hospital Universitario Doce de Octubre. Departamento de Oncologia Médica) ; Baron, A D (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ; Okusaka, T (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ; Yoshino, T (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Yoon, H H (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ; Das, M (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, D (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Binder, P (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Sashegyi, A (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Chau, I (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. [...]
2017 - 10.1093/annonc/mdx514
Annals of Oncology, Vol. 28 (september 2017) , p. 2932-2942  
2.
7 p, 176.2 KB Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients : an expert taskforce review / García-Foncillas, J (Hospital Universitario Fundación Jiménez Díaz) ; Alba, E (Hospital Universitario Regional Virgen de la Victoria, IBIMA, Málaga) ; Aranda, E (Hospital Reina Sofía, Cordoba) ; Díaz Rubio, E (Universidad Complutense de Madrid. Hospital Clínico San Carlos) ; López López, R (Hospital Clínico Universitario (Santiago de Compostela)) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona) ; Vivancos, A (Vall d'Hebron Institut d'Oncologia)
The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. [...]
2017 - 10.1093/annonc/mdx501
Annals of Oncology, Vol. 28 (september 2017) , p. 2943-2949  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.